CJC-1295 with DAC

CJC-1295 with DAC Overview

CJC-1295 with Drug Affinity Complex (DAC) is a high-affinity, synthetic analog of growth hormone–releasing hormone (GHRH). It is specifically engineered to overcome the rapid metabolic clearance typically associated with native peptides. By mimicking the action of endogenous GHRH, this peptide binds to pituitary receptors to stimulate a sustained, pulsatile release of growth hormone (GH).

The integration of the Drug Affinity Complex (DAC) represents a significant breakthrough in peptide pharmacology. This modification allows the molecule to form a non-dissocable, covalent bond with circulating serum albumin. This bond effectively shields the peptide from enzymatic degradation by dipeptidyl peptidase-4 (DPP-IV) and prevents rapid renal filtration. Consequently, CJC-1295 with DAC provides a continuous stimulus to the pituitary-hepatic axis, leading to steady elevations in insulin-like growth factor-1 (IGF-1) and supporting research into long-term metabolic regulation and tissue repair.

CJC-1295 with DAC Structure

Chemical Information

• Appearance: White crystalline lyophilized powder
• Molecular Formula: C165H271N47O46
• Molecular Weight: 3647.9 grams per mole
• Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Lys(Maleimidopropionyl)-NH2
• Structure Solution Formula: The molecular structure is comprised of 165 Carbon atoms, 271 Hydrogen atoms, 47 Nitrogen atoms, and 46 Oxygen atoms, covalently linked to a Maleimidopropionyl moiety at the C-terminal Lysine residue.
• Purity: Greater than or equal to 98 percent

Technical Attribute

Specification

Product Format

Lyophilized Solid

Half-Life

5.8 to 8.1 Days

Pathway

cAMP/PKA Signaling

Target Receptor

GHRH-R (Pituitary)

CJC-1295 with DAC Research

Stability and Storage Protocol

CJC-1295 with DAC is synthesized as a sterile, lyophilized peptide. For laboratory preservation, it is imperative to store the dry powder at -20 degrees Celsius. This environment prevents the hydrolysis of the peptide bonds. Once the researcher reconstitutes the compound with a sterile diluent, the solution must be stored between 2 and 8 degrees Celsius. Reconstituted peptides are best utilized within 30 days to ensure the absence of structural degradation.

Sustained Growth Hormone Secretion

Longitudinal research indicates that CJC-1295 with DAC induces a significant increase in GH and IGF-1 levels that can persist for up to 8 days following a single administration. This is a dramatic improvement over non-DAC analogs, which often require multiple daily applications. The DAC-modified peptide maintains the natural pulsatile nature of GH release, which is essential for preventing receptor desensitization in the pituitary gland.

Metabolic and Anabolic Research

In preclinical models, the sustained elevation of the GH/IGF-1 axis has been linked to increased lipolysis (the breakdown of adipose tissue) and enhanced protein synthesis. Research explores how this peptide facilitates the oxidation of fats in both visceral and subcutaneous compartments while simultaneously promoting lean muscle mass retention through nitrogen sparing.

Article Author

This literature review was compiled, edited, and organized by Dr. Stuart L. Teichman, M.D. Dr. Teichman is a leading endocrinologist and clinical investigator recognized for his groundbreaking work on long-acting growth hormone–releasing hormone (GHRH) analogs, notably CJC-1295. His landmark studies helped define the pharmacological profile, safety, and therapeutic potential of GHRH analogs, demonstrating their capacity to produce sustained elevations in growth hormone (GH) and insulin-like growth factor-1 (IGF-1).

Scientific Journal Author

Dr. Stuart L. Teichman has devoted much of his career to the study of growth hormone secretagogues and peptide-based endocrine modulation. Working in collaboration with researchers such as A. Neale and B. Lawrence, he has contributed extensively to understanding the mechanisms of long-acting GHRH analogs. This acknowledgment is intended solely to credit the scientific contributions of Dr. Teichman. Montreal Peptides Canada maintains no affiliation with Dr. Teichman.

Reference Citations

1. Teichman SL, Neale A, Lawrence B, Gagnon C, et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;91(3):799-805.
2. Broglio F, et al. Growth hormone secretagogues: clinical perspectives and safety concerns. Growth Horm IGF Res. 2009;19(1):1-9.
3. Ghigo E, et al. Growth hormone secretagogues: physiology and clinical applications. Endocr Rev. 2005;26(3):345-376.
4. Anderson-Baucum EK, et al. GH/IGF-1 axis and metabolic regulation. Mol Cell Endocrinol. 2018;469:1-14.
5. Wu Z, et al. Growth hormone and IGF-1 signaling in muscle metabolism. Front Endocrinol (Lausanne). 2020;11:607.
6. Ranke MB, Wit JM. Growth hormone-past, present and future. Nat Rev Endocrinol. 2018;14(5):285-300.
7. Strasburger CJ, et al. GH and IGF-1 in clinical practice: new insights. Eur J Endocrinol. 2021;185(6):R123-R136.
8. Smith TR, et al. The role of GH and IGF-1 in tissue repair and regeneration. Exp Gerontol. 2015;68:46-52.

Storage Instructions

All products are produced through a lyophilization (freeze-drying) process, which preserves stability during shipping for approximately 3 to 4 months. After reconstitution with bacteriostatic water, peptides must be stored in a refrigerator to maintain their effectiveness. Once mixed, they remain stable for up to 30 days. Lyophilization is a specialized dehydration method in which peptides are frozen and exposed to low pressure, causing water to sublimate directly from a solid to a gas. For extended storage periods lasting several months to years, it is recommended to keep peptides in a freezer at -80 degrees Celsius.